-
4-(Benzyloxy)-3,3-diethyl-2H-benzo[g]indole-2,5(3H)-dione
-
BD017764202642218-43-598%
-
¥3118.010mg
-
N-(2-Chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide
-
BD35158302962-49-898%
-
¥360.05g
-
2-[2,4-Bis(trifluoromethyl)imidazo[1,2-a]1,8-naphthyridin-8-yl]-1,3,4-oxadiazole
-
BD00871824691868-88-990%
-
¥323.0100mg
-
N-Methyl-1-(2-(naphthalen-1-ylthio)phenyl)methanamine hydrochloride
-
BD7646392070014-98-998%
-
¥1181.010mg
-
6-(Cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide
-
BD011326511609392-27-999%
-
¥999.01g
-
2-(2,6-Difluorophenyl)-4-((4-(pyrrolidine-1-carbonyl)phenyl)amino)-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one
-
BD015549202244061-66-198%
-
¥3300.0100mg
-
(R)-2-((5-Methoxy-2-(methylamino)pyrimidin-4-yl)amino)hexan-1-ol
-
BD011212022215120-36-698%
-
¥1153.050mg
-
Anifrolumab
-
BD015954461326232-46-598%
-
¥1800.01mg
-
Sodium (5R,7R,8R,12aR,14R,15R,15aS,16R)-7-(2-amino-6-oxo-3,6-dihydro-9H-purin-9-yl)-14-(6-amino-9H-purin-9-yl)-15,16-dihydroxyoctahydro-12H-5,8-methanofuro[3,2-l][1,3,6,9,11]pentaoxa[2,10]diphosphacyclotetradecine-2,10-bis(olate) 2,10-dioxide
-
BD014716272734858-36-598%
-
¥2130.01mg
-
1-((4-(4-Fluorophenyl)-6-methoxy-2H-chromen-3-yl)methyl)pyrrolidine hydrochloride
-
BD008280611704801-24-098%
-
¥722.050mg
-
Faralimomab
-
BD129986167816-91-398%
-
¥
-
Monalizumab
-
BD015875791228763-95-895%
-
¥
-
ODN 1585
-
BD01567157386832-46-898%
-
¥
-
Rontalizumab
-
BD01667623948570-30-795%
-
¥
-
EGFR-IN-11
-
BD013053532463200-44-298%
-
¥
-
Emapalumab (anti-IFNγ)
-
BD015138431709815-23-595%
-
¥
-
Sifalimumab
-
BD015796601006877-41-398%
-
¥
-
1-((S)-3-(3,4-Dichlorophenyl)piperidin-1-yl)-3-((R)-1-(methylsulfonyl)pyrrolidin-3-yl)prop-2-yn-1-one
-
BD018381092875046-27-698%
-
¥
-
Dazukibart
-
BD023791812639474-65-895%
-
¥